Kenta Fujimura, OTR, BS, Hitoshi Kagaya, MD, DMSc, Hisae Onaka, OTR,
Yuki Okochi, OTR, Masayuki Yamada, OTR, MS, Toshio Teranishi, RPT, PhD,
Yoshikiyo Kanada, RPT, DMSc, Eiichi Saitoh, MD, DMSc
Jpn J Compr Rehabil Sci 8: 4-9, 2017
Objective: We investigated the effect of botulinum
toxin type A for upper limb spasticity on activities of
daily living using the Disability Assessment Scale
(DAS).
Methods: The subjects were 47 patients who received
botulinum therapy for upper limb spasticity. They
were assessed before administration and 2, 6, and 12
weeks after administration by using the DAS, the
Modified Ashworth Scale (MAS), and upper-limbrelated
parameters from the Fugl-Meyer Assessment
(FMA).
Results: DAS scores for hygiene, dressing, and limb
position improved significantly 2 and 6 weeks after
administration (p < 0.05), but there was no significant
change in pain. MAS scores exhibited significant
improvement 2, 6, and 12 weeks after administration,
and the total scores for FMA upper-limb parameters
exhibited significant improvement 2 and 6 weeks after
administration (p < 0.05).
Conclusion: Botulinum therapy contributes to improving
not only the spasticity itself, but also to improving
difficulties in activities of daily living associated with
upper limb spasticity.
Key words: spasticity, BoNT-A, activities of daily living, upper limb function, Disability Assessment Scale